Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy

Cardiovasc Interv Ther. 2017 Jan;32(1):53-55. doi: 10.1007/s12928-015-0364-y. Epub 2015 Oct 31.

Abstract

A 42-year-old male with a history of smoking and dyslipidemia was admitted due to ST-elevation myocardial infarction. Coronary angiography showed severe stenosis in proximal right coronary artery (RCA) and total occlusion in mid RCA. Absorb everolimus-eluting bioresorbable scaffolds were deployed in mid and proximal RCA. The patient was discharged with dual anti-platelet therapy. Patient was admitted 15-months later due to acute coronary syndrome with scaffold thrombosis. Both aspirin and clopidogrel had been discontinued 1 month prior to the second event because of general malaise. Therefore, either aspirin or clopidogrel should have been continued even after 1 year following stent implantation.

Keywords: BRS; BVS; DAPT; Stent thrombosis; Very late scaffold thrombosis.

Publication types

  • Case Reports

MeSH terms

  • Absorbable Implants / adverse effects*
  • Adult
  • Clopidogrel
  • Coronary Angiography
  • Coronary Thrombosis / diagnosis
  • Coronary Thrombosis / etiology*
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / surgery*
  • Drug-Eluting Stents*
  • Everolimus / pharmacology*
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Male
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Complications
  • Prosthesis Design
  • ST Elevation Myocardial Infarction / diagnosis
  • ST Elevation Myocardial Infarction / surgery*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Tissue Scaffolds / adverse effects*
  • Withholding Treatment

Substances

  • Immunosuppressive Agents
  • Platelet Aggregation Inhibitors
  • Everolimus
  • Clopidogrel
  • Ticlopidine